Potente hæmmere af cytokrom P450 3A4 forøger risikoen for myopati og rhabdomyolyse ved at øge koncentrationen af HMG- CoA reduktasehæmmeraktivitet i plasma i forbindelse med simvastatinbehandling.
Potent inhibitors of cytochrome P450 3A4 increase the risk of myopathy and rhabdomyolysis by increasing the concentration of HMG-CoA reductase inhibitory activity in plasma during simvastatin therapy.